The nascent application of AI in biotech and drug discovery is helping fuel a surge in valuations of venture-backed biopharma startups.
AI could streamline the cumbersome process of shepherding new drugs to market through clinical trials and FDA approval. Hefty new fund launches aim to ensure capital will support top startups, and operators are paying attention to up-and-coming AI applications.
VC firms have been signing big checks to companies fusing machine learning with biotech research.
Altos Labs, which is pioneering ways to rejuvenate ailing cells by tapping into its large language models—has raised at least $4.07 billion, according to PitchBook data. And in April, Xaira Therapeutics burst onto the scene with a $1 billion Series A deal that valued the early-stage startup at $1.7 billion.
Here are the 10 most active VCs in biotech backing the biological interventions that could help us live longer, healthier lives.
Featured image by MirageC via Getty Images
